JP2012255026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012255026A5 JP2012255026A5 JP2012196525A JP2012196525A JP2012255026A5 JP 2012255026 A5 JP2012255026 A5 JP 2012255026A5 JP 2012196525 A JP2012196525 A JP 2012196525A JP 2012196525 A JP2012196525 A JP 2012196525A JP 2012255026 A5 JP2012255026 A5 JP 2012255026A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutical composition
- compound
- composition according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000017497 prostate disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65739005P | 2005-03-02 | 2005-03-02 | |
| US60/657,390 | 2005-03-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007558143A Division JP5130453B2 (ja) | 2005-03-02 | 2006-03-02 | 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012255026A JP2012255026A (ja) | 2012-12-27 |
| JP2012255026A5 true JP2012255026A5 (enExample) | 2013-02-21 |
| JP5613206B2 JP5613206B2 (ja) | 2014-10-22 |
Family
ID=36941503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007558143A Expired - Lifetime JP5130453B2 (ja) | 2005-03-02 | 2006-03-02 | 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性 |
| JP2012196525A Expired - Lifetime JP5613206B2 (ja) | 2005-03-02 | 2012-09-06 | 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007558143A Expired - Lifetime JP5130453B2 (ja) | 2005-03-02 | 2006-03-02 | 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7875599B2 (enExample) |
| EP (2) | EP2206719B1 (enExample) |
| JP (2) | JP5130453B2 (enExample) |
| KR (1) | KR101380959B1 (enExample) |
| CN (2) | CN103349664A (enExample) |
| AT (1) | ATE482969T1 (enExample) |
| AU (1) | AU2006218711B2 (enExample) |
| BR (1) | BRPI0607523A2 (enExample) |
| CA (1) | CA2599953C (enExample) |
| DE (1) | DE602006017175D1 (enExample) |
| DK (2) | DK1853619T3 (enExample) |
| EA (1) | EA019560B1 (enExample) |
| ES (2) | ES2528055T3 (enExample) |
| IL (3) | IL185608A (enExample) |
| MX (1) | MX2007010593A (enExample) |
| NZ (1) | NZ561571A (enExample) |
| PL (2) | PL1853619T3 (enExample) |
| PT (2) | PT2206719E (enExample) |
| SI (2) | SI1853619T1 (enExample) |
| WO (1) | WO2006093993A1 (enExample) |
| ZA (1) | ZA200708106B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
| PT2206719E (pt) * | 2005-03-02 | 2015-02-05 | Univ Maryland | Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno |
| CA2726734C (en) | 2007-06-06 | 2014-10-07 | University Of Maryland, Baltimore | Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer |
| US20110105445A1 (en) * | 2008-03-12 | 2011-05-05 | University Of Maryland, Baltimore | Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer |
| US20100048524A1 (en) * | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| GB2470700B (en) | 2008-03-25 | 2012-08-08 | Univ Maryland | C-17 heteroaryl steroidal CYP17 inhibitors |
| US8785423B2 (en) * | 2008-04-14 | 2014-07-22 | University Of Maryland, Baltimore | Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases |
| US20110190323A1 (en) | 2008-08-28 | 2011-08-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses thereof |
| WO2010062506A2 (en) * | 2008-10-28 | 2010-06-03 | Lead Therapeutics, Inc. | Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors |
| WO2010091306A1 (en) * | 2009-02-05 | 2010-08-12 | Tokai Pharmaceuticals | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| US20110319369A1 (en) * | 2009-02-05 | 2011-12-29 | Tokai Pharmaceuticals, Inc. | Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent |
| US8791095B2 (en) | 2009-02-05 | 2014-07-29 | Tokai Pharmaceuticals, Inc. | Steroidal CYP17 inhibitors/antiandrogens |
| MA33451B1 (fr) | 2009-06-26 | 2012-07-03 | Novartis Ag | Dérivés d'imidazolidin-2-one 1,3-disubstitués en tant qu'inhibiteurs de cyp 17 |
| BR112012002797A2 (pt) * | 2009-08-07 | 2019-09-24 | Tokai Pharmaceuticals Inc | tratamento de câncer de próstata |
| WO2011059969A2 (en) * | 2009-11-13 | 2011-05-19 | Tokai Pharmaceuticals, Inc. | Mammalian metabolites of steroids |
| EP2506855A4 (en) * | 2009-11-30 | 2014-07-30 | Harbor Biosciences Inc | ANTICARCINOMA COMPOUNDS AND SCREENING METHODS |
| JP2013537210A (ja) | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| CA2819515A1 (en) * | 2010-12-16 | 2012-06-21 | Biomarin Pharmaceutical Inc. | Cyp11b, cyp17, and/or cyp21 inhibitors |
| EA023064B1 (ru) | 2011-04-28 | 2016-04-29 | Новартис Аг | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |
| CN103813794A (zh) * | 2011-07-18 | 2014-05-21 | 拓凯制药公司 | 用于治疗前列腺癌的新型组合物及方法 |
| AU2012358219A1 (en) * | 2011-12-22 | 2014-07-10 | Tokai Pharmaceuticals, Inc. | Methods and compositions for combination therapy using P13K/mTOR inhibitors |
| EP2968370A4 (en) | 2013-03-14 | 2016-09-21 | Univ Maryland | AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF |
| US9694005B2 (en) | 2013-04-04 | 2017-07-04 | University Of Maryland, Baltimore | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity |
| EP3033088A4 (en) | 2013-08-12 | 2017-03-08 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| CA2934819A1 (en) | 2013-12-24 | 2015-07-02 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| CN103694299A (zh) * | 2014-01-13 | 2014-04-02 | 中国药科大学 | 甾体类雄激素受体抑制剂、其制备方法及其医药用途 |
| CN105732759A (zh) * | 2015-01-29 | 2016-07-06 | 苏州晶云药物科技有限公司 | (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法 |
| WO2016182932A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| WO2017004411A1 (en) | 2015-07-01 | 2017-01-05 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| US10682362B2 (en) | 2015-10-14 | 2020-06-16 | Wayne State University | Treatments and diagnostics for cancers |
| IT201600121375A1 (it) * | 2016-11-30 | 2018-05-30 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE |
| US11390645B2 (en) | 2016-08-08 | 2022-07-19 | Industriale Chimica S.R.L. | Process for the preparation of 3β-hydroxy-17-(1H-benzimidazol-1-YL) androsta-5,16-diene |
| IT201600083406A1 (it) * | 2016-08-08 | 2018-02-08 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE |
| AU2019222651B2 (en) * | 2018-02-13 | 2024-08-22 | Dana-Farber Cancer Institute, Inc. | Cyclin-dependent kinase inhibitors and methods of use |
| AU2019222652B2 (en) | 2018-02-13 | 2021-09-02 | Dana-Farber Cancer Institute, Inc. | Cyclin-dependent kinase degraders and methods of use |
| CA3159284A1 (en) | 2019-11-26 | 2021-06-03 | Dana-Farber Cancer Institute, Inc. | Potent and selective azaindole inhibitors of cdk8 and cdk19 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA27440A (en) | 1887-08-16 | James T. Walsh | Art of making sheet metal cans, for packing meats, fruits, vegetables, etc. | |
| CH621803A5 (enExample) * | 1974-08-08 | 1981-02-27 | Siphar Sa | |
| US5604213A (en) * | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| US5994335A (en) * | 1997-10-17 | 1999-11-30 | The University Of Maryland, Baltimore | 17-azolyl steroids useful as androgen synthesis inhibitors |
| WO2005014023A1 (en) | 2003-07-29 | 2005-02-17 | Dompe' Pha.R.Ma S.P.A. | Pharmaceutical combination of g-csf and plgf useful for blood stem cell |
| PT2206719E (pt) | 2005-03-02 | 2015-02-05 | Univ Maryland | Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno |
-
2006
- 2006-03-02 PT PT101507630T patent/PT2206719E/pt unknown
- 2006-03-02 US US11/817,550 patent/US7875599B2/en active Active
- 2006-03-02 EP EP10150763.0A patent/EP2206719B1/en not_active Expired - Lifetime
- 2006-03-02 PL PL06736460T patent/PL1853619T3/pl unknown
- 2006-03-02 WO PCT/US2006/007143 patent/WO2006093993A1/en not_active Ceased
- 2006-03-02 ES ES10150763.0T patent/ES2528055T3/es not_active Expired - Lifetime
- 2006-03-02 PT PT06736460T patent/PT1853619E/pt unknown
- 2006-03-02 ES ES06736460T patent/ES2353413T3/es not_active Expired - Lifetime
- 2006-03-02 MX MX2007010593A patent/MX2007010593A/es active IP Right Grant
- 2006-03-02 SI SI200630861T patent/SI1853619T1/sl unknown
- 2006-03-02 AU AU2006218711A patent/AU2006218711B2/en not_active Expired
- 2006-03-02 CN CN2013101036754A patent/CN103349664A/zh active Pending
- 2006-03-02 DE DE602006017175T patent/DE602006017175D1/de not_active Expired - Lifetime
- 2006-03-02 PL PL10150763T patent/PL2206719T3/pl unknown
- 2006-03-02 EP EP06736460A patent/EP1853619B1/en not_active Expired - Lifetime
- 2006-03-02 NZ NZ561571A patent/NZ561571A/en not_active IP Right Cessation
- 2006-03-02 JP JP2007558143A patent/JP5130453B2/ja not_active Expired - Lifetime
- 2006-03-02 SI SI200631883T patent/SI2206719T1/sl unknown
- 2006-03-02 DK DK06736460.4T patent/DK1853619T3/da active
- 2006-03-02 CA CA2599953A patent/CA2599953C/en not_active Expired - Lifetime
- 2006-03-02 EA EA200701872A patent/EA019560B1/ru not_active IP Right Cessation
- 2006-03-02 AT AT06736460T patent/ATE482969T1/de active
- 2006-03-02 KR KR1020077022440A patent/KR101380959B1/ko not_active Expired - Fee Related
- 2006-03-02 DK DK10150763.0T patent/DK2206719T3/en active
- 2006-03-02 BR BRPI0607523-1A patent/BRPI0607523A2/pt not_active IP Right Cessation
- 2006-03-02 CN CNA2006800064632A patent/CN101155823A/zh active Pending
-
2007
- 2007-08-30 IL IL185608A patent/IL185608A/en not_active IP Right Cessation
- 2007-09-20 ZA ZA200708106A patent/ZA200708106B/xx unknown
-
2011
- 2011-01-06 IL IL210480A patent/IL210480A/en not_active IP Right Cessation
- 2011-01-06 IL IL210478A patent/IL210478A0/en unknown
-
2012
- 2012-09-06 JP JP2012196525A patent/JP5613206B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518107A5 (enExample) | ||
| JP2015078230A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2011102304A5 (enExample) | ||
| JP2012502037A5 (enExample) | ||
| JP2017537066A5 (enExample) | ||
| JP2013014622A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| HRP20240168T1 (hr) | Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije | |
| JP2011068653A5 (enExample) | ||
| JP2015523407A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2015155440A5 (enExample) | ||
| JP2014521735A5 (enExample) | ||
| JP2009545527A5 (enExample) | ||
| JP2016517888A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2015529234A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| GB2495676A (en) | Use of binders for manufacturing storage stable formulations | |
| JP2014515013A5 (enExample) |